Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 12/20 | 0.41 |
| ▸ | PLK1 | P53350 | 4/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555811 | 0.95 | IGF1R (0.42) | IGF1RPLK1CDK2IDH1KCNH2 | |
| SCHEMBL3554553 | 0.88 | IGF1R (0.45) | IGF1RPLK1CDK2IDH1 | |
| SCHEMBL3543396 | 0.87 | IGF1R (0.43) | IGF1RPLK1CDK2IDH1KCNH2 | |
| SCHEMBL3550094 | 0.87 | PLK1 (0.39) | IGF1RPLK1CDK2IDH1RPS6KB1 | |
| SCHEMBL3556879 | 0.86 | IGF1R (0.42) | IGF1RPLK1CDK2HRH4RPS6KB1 | |
| SCHEMBL3551627 | 0.86 | PLK1 (0.46) | IGF1RPLK1IDH1RPS6KB1 | |
| SCHEMBL3555055 | 0.85 | IGF1R (0.42) | IGF1RPLK1CDK2IDH1KCNH2 | |
| SCHEMBL3556604 | 0.85 | IGF1R (0.43) | IGF1RPLK1CDK2IDH1 | |
| SCHEMBL3555421 | 0.82 | IGF1R (0.48) | IGF1RPLK1CDK2KCNH2 | |
| SCHEMBL3551353 | 0.82 | IGF1R (0.41) | IGF1RPLK1CDK2IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101048406-B | Novel substituted imidazole derivatives | BANYU PHARMA CO LTD | 2010-12-22 | — | — | CN | disclosed |
| US-7718801-B2 | Substituted imidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| CN-101048406-A | Novel substituted imidazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-10-03 | — | — | CN | disclosed |
| EP-1790650-A1 | NOVEL SUBSTITUTED IMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070894-A1 | Novel Substituted Imidazole Derivative | PLK1, CDK1, CDK11A | IGF1R 101/4885PLK1 1/4885CDK2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.